News
BEAM
22.74
-3.11%
-0.73
Beam Therapeutics: A 'Hold' Amid High Valuation And Uncertain Revenue Prospects
Beam Therapeutics is a biotech firm focused on developing precision genetic treatments using base editing technology. The company has secured $675 million in upfront payments from agreements with Pfizer. Beam's revenue is less predictable due to a lack of product sales. The firm's cash runway is around 2.1 years. Beam is trading at a high valuation multiple, which detracts from its investment appeal.
Seeking Alpha · 1d ago
Expert Ratings For Beam Therapeutics
Beam Therapeutics is a biotechnology company engaged in creating genetic medicines based on its base editing technology. The company has an average price target of $46.2. 5 analysts have provided ratings for Beam Therapeutic in the latest quarter. The average 12-month price target reflects an increase of 52.32% from the previous average of $30.33.
Benzinga · 1d ago
Beam Therapeutics Price Target Maintained With a $57.00/Share by Wedbush
Dow Jones · 1d ago
Wedbush Reiterates Outperform on Beam Therapeutics, Maintains $57 Price Target
Benzinga · 1d ago
Beam Therapeutics: A Strong Buy on Gene Editing Advancements and Strategic Growth Potential
TipRanks · 1d ago
Beam Therapeutics Stock (NASDAQ:BEAM): Investing in Cutting-Edge Gene Editing
TipRanks · 2d ago
Weekly Report: what happened at BEAM last week (0415-0419)?
Weekly Report · 2d ago
First Week of June 21st Options Trading For Beam Therapeutics
NASDAQ · 5d ago
Tracking Cathie Wood's ARK Invest 13F Portfolio - Q1 2024 Update
Seeking Alpha · 5d ago
Weekly Report: what happened at BEAM last week (0408-0412)?
Weekly Report · 04/15 09:17
Popular Crypto Trader Shares 2024 Predictions For These Three Altcoins
Popular pseudonymous crypto analyst Altcoin Sherpa on Friday shared his insights on three altcoins: Beam, Arbitrum, and Render. The analyst believes BEAM is a significant, indexed bet on the cryptocurrency gaming sector. He predicts a potential decline in the price of ARB to $1.20 or lower.
Benzinga · 04/12 17:55
Weekly Report: what happened at BEAM last week (0401-0405)?
Weekly Report · 04/08 09:18
Lacklustre Performance Is Driving Beam Therapeutics Inc.'s (NASDAQ:BEAM) Low P/S
Beam Therapeutics Inc. Has a price-to-sales ratio of 5.9x. The company has been growing revenue more than most other biotech companies. However, the company's P/S ratio is lower than the average for the industry. It's expected to decline 47% each year over the next three years.
Simply Wall St · 04/07 13:31
Beam Therapeutics Inc.: Report of proposed sale of securities
Press release · 04/05 02:04
U.S. RESEARCH ROUNDUP-Ally Financial, GE Vernova, Navient
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Ally Financial, GE Vernova, Navient and Navient are among the companies. Analysts cut ratings and target prices on several companies on Wednesday. Some analysts raised their targets for the companies, others cut them.
Reuters · 04/03 07:28
BEAM THERAPEUTICS INC <BEAM.O>: LEERINK PARTNERS CUTS TARGET PRICE TO $27 FROM $28
Reuters · 04/03 04:21
Beam Therapeutics: A Buy Rating Amidst Gene Editing Industry Developments
TipRanks · 04/02 23:25
Beam Therapeutics Inc.: Statement of changes in beneficial ownership of securities
Press release · 04/02 20:38
Gene Therapy Side Effects: Verve Therapeutics Halts Enrollment Of Lead Gene Therapy Trial In Patients With Bad Cholesterol
Verve Therapeutics announces update from Heart-1 Phase 1b trial of VERVE-101. Verve-101 is being evaluated in patients with a genetic condition that leads to high cholesterol levels. The treatment is supposed to permanently turn off a protein called PCSK9.
Benzinga · 04/02 16:19
Biotech Roundtable: Who will bring the next CRISPR drug to market?
Healthcare Biotech Roundtable: Who will bring the next CRISPR drug to market? CRisPR gene editing technology has been heralded as a revolutionary breakthrough in drug development. Last fall, the FDA approved the first CRISpr product for the US market. Seeking Alpha asked three analysts to weigh in on the technology and companies working in it.
Seeking Alpha · 04/02 15:36
More
Webull provides a variety of real-time BEAM stock news. You can receive the latest news about Beam Therapeutics Inc. through multiple platforms. This information may help you make smarter investment decisions.
About BEAM
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases, as well as immunology/oncology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301 and BEAM-201. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents. BEAM-201 is an anti-CD7 CAR-T product candidate.